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Introduction
Alzheimer’s disease (AD) is the leading neuro  degenera-
tive disorder and accounts for approximately two-thirds 
of dementia. AD aﬀ  ects around 10% of people above the 
age of 75, and in the United States approximately 4 million 
people suﬀ  er from AD-related dementia with annual asso-
ciated costs estimated to be approximately $100 billion.
Th  e diagnosis of AD currently depends on patients 
having impairments in memory function and at least one 
other cognitive domain, to the extent that it impairs daily 
function. AD is a clinical diagnosis mainly based on 
NINCDS-ADRDA criteria [1] and DSM-IV criteria [2]. 
Th   ese criteria were revised recently by the international 
working group for new research criteria for the diagnosis 
of AD [3]. Th   e cardinal features are late-onset impairment 
of short-term recall [4,5] associated with deterioration of 
language and visuo-spatial functions [6,7] in the absence 
of disturbance of con  scious  ness and systemic disorders. 
A postmortem diag  nosis of AD is based on the presence 
of extracellular senile plaques positive for β-amyloid 
protein (Aβ), dystrophic neurites, and intracellular 
neuroﬁ   brillary tangles in the brain. Neuroﬁ  brillary 
tangles contain a hyperphosphorylated form of the 
microtubule-associated protein, tau, and also ubiquitin 
[8]. Amyloid plaques are composed of 40 to 42 amino 
acid Aβ-folded peptides. Two types of amyloid plaques 
are present in neuro  degenerative diseases: one with a 
central core and radiating ﬁ  brils, the ﬁ  brillar amyloid; 
and second, the diﬀ  use (amorphous) amyloid. A small 
degree of AD-like pathology can be found in cognitively 
normal individuals over the age of 75 but large deposits 
of amyloid suggest AD.
Until a few years ago, magnetic resonance imaging 
(MRI) and cerebral blood ﬂ   ow studies were the only 
methods by which we could gain information about the 
changes in the living human brain. Structural MRI and 
blood ﬂ  ow studies, however, depend on gross changes in 
brain structure and function that suggest gross atrophy 
or a functional alteration that has already occurred. 
Th  ese markers are thus secondary phenomena and are 
therefore not the primary targets for following patients 
over a period of time or for diagnosing very early and 
subtle changes. Clinico-pathological studies suggest that 
neuronal loss has already occurred by the time gross 
atrophy is detected by MRI. Positron emission tomo-
graphy (PET) with [18F]ﬂ   uorodeoxyglucose adds to the 
diag  nostic and prognostic accuracy in the clinical evalu  a-
tion of AD [9], but the technique still detects an indirect 
measure of disease presence or progression.
Modiﬁ  cation of the polar amyloid binding histological 
dye, thioﬂ  avin T, led to the ﬁ  nding that neutral benzo-
thiazoles bind to amyloid with high aﬃ   nity and addi-
tionally cross the blood–brain barrier [10]. Th  e benzo-
thiazole amyloid binding agent 2-(4’-methyl-amino-
phenyl)-benzothiazole and related compounds bind to 
amyloid with low nanomolar aﬃ   nity, enter the brain in 
amounts suﬃ   cient for imaging with PET and clear rapidly 
from normal brain tissue [11,12]. At the low nanomolar 
concentrations typically administered during PET studies, 
2-(4’-methyl-amino-phenyl)-benzothiazole binds to extra-
cellular amyloid plaques in postmortem brain slices but 
not to intracellular neuroﬁ  brillary tangles. In vitro studies 
suggest that, while 2-(4’-methyl-amino-phenyl)-benzo-
thiazole binds to ﬁ  brillar Aβ deposits found in the cortex 
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A hydroxylated derivative of benzothiazole, N-methyl-
[11-C]2-(4’-methylaminophenyl)-6-hydroxybenzo-
thiazole – widely known as [11C]Pittsburgh Compound B 
([11C]PIB) – has been synthesised as a PET tracer and 
studied in humans. An initial study showed that [11C]PIB 
shows a signiﬁ  cant uptake in AD subjects compared with 
the control subjects [13]. Following this initial study, 
several other studies have shown similar ﬁ  ndings in AD 
and in other dementia [14-16]. Postmortem studies have 
shown a direct correlation between Aβ plaque and in vivo 
[11C]PIB retention measured by PET imaging. Studies 
have shown that the ﬂ  uorescent PIB ana  logue 6-CN-PIB 
labelled Aβ-containing structures, includ  ing compact/
cored, diﬀ   use, neuritic and non-neuritic Aβ plaques. 
6-CN-PIB also labelled vascular amyloid, but no signal 
was detected in neurophil threads or dystrophic neurites 
and a signal was only detected sporadically on an 
extracellular ghost tangle. A patient who underwent 
postmortem neuropathological examinations 10 months 
after [11C]PIB PET imaging demonstrated that in vivo 
retention corre  lated directly with postmortem 
quantiﬁ  cation of PIB and Aβ plaque load but not with 
neuroﬁ  brillary tangle or other neuroﬁ  brillary pathology 
[17].
In the present article, a review of the technical aspects 
of amyloid imaging for AD will be presented. We 
therefore ﬁ  rst introduce the general procedure for in vivo 
molecular imaging in man using PET. We then go on to 
describe image processing and data analysis.
Molecular imaging in man
Th   e molecular imaging process is shown in Figure 1. In 
the ﬁ  rst step (top right of the ﬁ  gure), radioisotopes are 
produced either in dedicated cyclotrons – for example, 
the positron emitters 11C or 18F – or in special radio-
nuclide generators – for example, the single-photon 
emitter  99mTc. After the production of the radioisotope, 
the radio  labelled compounds for the imaging study are 
produced in a radiochemistry system. Various routes for 
the radiochemistry usually exist; for example, for 18F-
labelled tracers by nucleophilic or electrophilic reaction. 
Quality control is performed to check and conﬁ  rm that 
the radiopharmaceutical product is within predetermined 
speciﬁ   cations; for example, for speciﬁ   c activity, radio-
chemical purity or sterility.
Th   e basis of tracer imaging is the detection by external 
devices of the radiation emitted from the radiolabel 
attached to the tracer injected into humans. In most 
cases, the nuclear disintegration of the radioisotope is 
detected via registering photons that are either 
uncorrelated (hence single-photon imaging) or that are 
paired as the result of positron annihilation. Th  is  imaging 
technique is then known as coincidence imaging or 
positron imaging, and is schematically shown in the scan 
box of Figure 1. A pair of photons resulting from the 
annihilation of a positron generated by the conversion of 
a proton in the nucleus is recorded as a line of response 
by the PET scanner. Tomographic image reconstruction 
techniques are subsequently employed to reconstruct a 
dynamic sequence of emission images from the brain 
scan [18]. Today, PET scanners operate in three-dimen-
sional mode, covering the entire brain in a single scan 
with an axial ﬁ  eld of view of at least 15 cm. Modern PET 
scanners are usually combined PET/computer tomo-
graphy systems as they include an integrated X-ray 
computer tomograph for the acquisition of photon 
attenu  ation images required for the correction of the PET 
images for the eﬀ  ects of photon attenuation and scatter. 
Combined PET and MRI systems are just emerging that 
combine the excellent contrast between grey and white 
matter provided by the magnetic resonance acquisition 
with the molecular images of the PET study.
Th   e most widely used method for the reconstruction of 
quantitative brain images using PET is ﬁ  ltered  back 
projec  tion, an analytical image reconstruction method. 
Filtered back projection is computationally fast and has 
linear proper  ties, which means the precision of the 
reconstructed images is independent of the location 
within the image and of the intensity of the object. 
Iterative image reconstruction, on the other hand, is 
computationally expensive and often only slowly 
converging and in an object-dependent manner. 
Iteratively reconstructed images are visually more appeal-
ing, because they do not exhibit the streak artefacts 
typical for ﬁ  ltered back projection reconstructed images. 
As the iterative image reconstruction allows one to more 
accurately model the entire imaging process, resolution 
eﬀ   ects can be included in the system description – 
images with higher spatial resolution than those from 
ﬁ  ltered back projection can therefore be obtained.
Th   e absolute quantiﬁ  cation of the radiotracer kinetics 
in the tomographic images normally requires an input 
function. Th  e input function is the time course of the 
radiotracer in the supply stream that drives the tissue 
response. Th  e time course of the concentration of the 
radiolabelled compound in arterial plasma therefore has 
to be measured. In contrast to the acquisition of the 
images, which is performed by a single instrument (a 
SPECT or PET camera), the measurement of the plasma 
input function requires the combination of several 
laboratory devices. Online blood detector systems are 
used to provide whole blood activity measurements of 
continuously withdrawn blood with excellent temporal 
resolution but with limited sensitivity due to their 
relatively small counting volume. Well counters or 
automated gamma counters are used to measure with 
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or, after centrifugation, of plasma samples. For 
radiotracers that undergo metabolism in the body, 
quantitative assays of the plasma samples to determine 
the fraction of radioactivity that is due to unmetabolised 
parent compound is required to obtain the input 
function. Th  e laboratory setup for these analyses often 
involves solid-phase extraction followed by HPLC or 
thin-layer chromatography. Figure 2 shows an example 
chromatogram obtained from an HPLC analysis run of a 
scan with [11C]PIB.
Image processing and data analysis
After completion of the PET scan and the reconstruction 
of the dynamic images from the emission scan, an 
integral or sum image is generated in order to perform a 
co-registration with a structural volumetric magnetic 
resonance image as shown in Figure 3. Th   is then allows 
the accurate deﬁ  nition of volumes of interest (VOIs) on 
the brain imaging data. Automated methods using atlases 
deﬁ  ned on brain templates are used as well as VOIs being 
manually outlined, particularly in cases with high levels 
of brain atrophy.
Using the set of VOIs deﬁ  ned, the dynamic PET images 
are then sampled and tissue time–activity curves gener-
ated. As is illustrated in Figure 4, these tissue time–
activity curves represent the measured activity concen-
tration averaged across the VOI – which implies that, in 
the ensemble of volume elements (voxels) comprising a 
VOI, all voxels share the same parameters of the under-
lying physiological and biochemical processes, and only 
diﬀ   er as they are diﬀ   erent realisations of the same 
random process. Th   is means that special attention has to 
be paid to tissue heterogeneity when VOIs are deﬁ  ned, 
and often magnetic resonance images segmented in 
diﬀ   erent tissue classes (grey matter, white matter and 
cerebrospinal ﬂ  uid) are employed for the deﬁ  nition of 
homogeneous VOIs. As an example, the diﬀ  erence in the 
[11C]PIB signal between cerebellar grey matter and 
cerebellar white matter is highlighted in Figure 3.
Th   e purpose of     tracer kinetic analysis (centre top box in 
Figure 1) is to disentangle the diﬀ  erent processes that 
jointly result in the tissue response curves obtained [19]. 
For amyloid imaging studies, the contributions to con-
sider are as follows. First, tracer delivery and washout  – 
as the amyloid imaging markers currently used (for 
Figure 1. Sch  ematic of the molecular imaging process illustrated by a positron emission tomography scan. FDG, fl  uorodeoxyglucose.
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BAY94-9172 and ﬂ  orbetapir ([18F]AV-45)) are thought to 
cross the blood–brain barrier by passive diﬀ  usion, the 
delivery to and washout from brain tissue of these 
radiotracers is governed by cerebral blood ﬂ  ow. A second 
contribution is speciﬁ  c binding – the association, and 
dissociation for reversibly binding ligands, of the radio-
ligand with the target (that is, Aβ). Another contribution 
is nonspeciﬁ  c binding – referring to any nonsaturable 
binding that occurs to other sites than Aβ (for example, 
to membranes or lipid fractions). A fourth contribution is 
radiolabelled metabolites – several of the [18F]-labelled 
radiotracers used for amyloid imaging have been 
reported to form radiolabelled metabolites in vivo that 
are also able to cross the blood–brain barrier [20]; part of 
the radioactivity signal measured in brain tissue is there-
fore due to the contamination with radiolabelled 
metabolites. Finally, vascular activity – owing to the 
spatial resolution of the positron cameras of several 
millimetres, any VOI deﬁ  ned in the brain contains a few 
per cent blood volume; the spill in of activity from the 
vasculature therefore needs to be accounted for.
Using mathematical modelling and parameter estima-
tion methods, system parameters such as rate constants, 
volumes of distribution or binding potentials [21] can be 
estimated from the dynamic imaging data. Th  e  outcome 
parameters chosen should, of all the contributions listed 
above, reﬂ   ect the speciﬁ   c binding to the maximum 
possible extent and should be insensitive to the other 
confounders. For example, it has been shown for [11C]PIB 
that the accumulation rate did not correlate with cerebral 
blood ﬂ  ow [22]. Th  e parameter estimates can either be 
obtained regionally for each VOI, or they can be calcu-
lated for each voxel individually and then again repre-
sented as an image that is often referred to as a para-
metric map [23] (Figure 5). Parametric maps can then be 
interrogated for parameter changes that do not corres-
pond to the anatomically predeﬁ  ned VOIs.
A variety of modelling approaches exists and they have 
been applied to amyloid imaging studies with [11C]PIB. 
Th  ese approaches range from compartmental models 
[24], through graphical analyses such as Logan plots [25] 
or Patlak plots [26,27], to spectral analysis [28] and 
reference tissue models [29,30]. In reference tissue 
models, the tissue time–activity curve of a region without 
speciﬁ  c binding is used as a substitute for the plasma 
Figure 2. Ana  lysis of radiolabelled metabolites in a plasma 
sample. Data from the 15-minute sample of a human subject 
injected with 370 MBq [11C]Pittsburgh Compound B ([11C]PIB), a 
marker of amyloid deposition in the brain. The plot shows the HPLC 
trace with three identifi  able peaks. The peak of the unmetabolised 
parent compound with about a 9-minute retention time follows 
two more hydrophylic metabolites that partly overlap. Insert: 
measurements of the fractions of radioactivity in plasma belonging 
to metabolite 1, metabolite 2 and [11C]PIB, respectively. Eight 
plasma samples were analysed for this 90-minute positron emission 
tomography scan. The plot illustrates that the parent [11C]PIB (red 
line) is rapidly metabolised in humans. Modifi  ed with permission 
from [42].
Figure 3. Sag  ittal image sections from a control subject and an Alzheimer’s disease patient. Sagittal image sections from (left) a control 
subject and (right) an Alzheimer’s disease (AD) patient. Positron emission tomography (PET) images (colour scale in the centre) were acquired in 
90-minute scans after bolus injection of 370 MBq [11C]Pittsburgh Compound B ([11C]PIB). The magnetic resonance (MR) images were co-registered 
to the PET images. Visual inspection reveals an increased uptake of [11C]PIB in the cortical areas of the AD patient and no obvious diff  erence in the 
cerebellum compared with the control subject.
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grey matter is widely used as a reference region because 
postmortem investi  gations conﬁ  rmed negligible concen-
trations of Aβ in cerebellar grey matter in this disease. 
However, careful validation of the reference region is 
required for each disease population.
One of the commonly used methods of analysis is the 
target to cerebellar ratio, commonly referred to as the 
RATIO method. Diﬀ   erent groups have used diﬀ  erent 
time points to create RATIO images from 40 to 
60  minutes, from 40 to 70 minutes and from 60 to 
90 minutes. Th  ese  diﬀ  erent time points largely give com-
parable results, however – and at later time points, while 
the signal increases, the noise also increases. Again, in 
diﬀ  erent studies, diﬀ  erent RATIO values have used as 
cut-oﬀ   points [31,32]. Some studies have used a strict 
cut-oﬀ   value of two standard deviations above the control 
mean for individual regions, while other studies have 
used much more liberal cut-oﬀ   values and a RATIO value 
of 1.4 or even 1.5. Even though diﬀ  erent scanners diﬀ  er 
Figure 4. Tis  sue time–activity curves. Tissue time–activity curves (TACs) from the two subjects shown in Figure 3 for four regions: cerebellar grey 
matter (cerebellum), frontal cortex, temporoparietal cortex and occipital cortex. (Left) Age-matched control subject. (Right) Alzheimer’s disease 
patient. TACs shown corrected for radioactive decay.
Figure 5. Par  ametric maps. Parametric images from the [11C]Pittsburgh Compound B ([11C]PIB) scans of the two subjects shown in Figure 3: top 
images, control subject; bottom images, Alzheimer’s disease (AD) patient. Images generated with spectral analysis; colour bars for each column 
indicate the image minimum and maximum values. The impulse response function (IRF) at 1 minute in the left column gives a refl  ection of tracer 
delivery. The cerebral blood fl  ow in most grey matter areas of the AD subject’s brain is lower than that in the elderly control subject. The IRF 
75-minute images in the centre give an indication of [11C]PIB retention in tissue. In the control subject, [11C]PIB is retained predominantly in the 
white matter; whereas in the AD patient, widespread [11C]PIB retention in cortical grey matter occurred with association cortical areas, in particular, 
being targeted. Note that the cerebellar grey matter in both the control subject as well as the AD patient shows only very little [11C]PIB retention. 
The total volume of distribution (VD) parametric images in the right column also refl  ect [11C]PIB uptake in tissue, but with a slightly lower contrast 
between grey matter and white matter than the IRF 75-minute parametric images.
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1.5 is clearly abnormal.
Less sophisticated but technically much simpler to 
perform than dynamic scans are static acquisitions. In 
this procedure, the time-course of activity is not 
measured but only an integral (sum) image of tissue 
activity of a certain period after tracer injection is 
acquired. By then it is assumed that the tracer has 
reached a state of pseudo-equilibrium so that the tissue 
activity–concentration ratio can be used as an apparent 
volume of distribution ratio [33] (Figure 6).
Statistical parametric mapping
Th  e statistical parametric mapping (SPM) method of 
analysis is an approach used to localise signiﬁ  cant changes 
in brain physiology or pharmacology. Th   is localisation is 
achieved by applying the general linear model to all 
independent voxels and creating an image of a statistic. 
SPM refers to the construction of spatially extended 
statistical processes to test hypotheses about regionally 
speciﬁ  c  eﬀ   ects. SPMs are image processes with voxel 
values that are, under the null hypothesis, distributed 
according to a known proba  bility density function 
(usually Gaussian). Th   ese statis  tical parametric maps are 
three-dimensional projec  tions of statistical functions that 
are used to characterise signiﬁ  cant regional brain diﬀ  er-
ences in imaging para  meters. Th  e theory of Gaussian 
ﬁ  elds is used to provide P values that are corrected for 
the brain volume analysed [34,35].
To implement voxel-based analysis of imaging data, the 
data from diﬀ   erent subjects must derive from 
homologous parts of the brain. Spatial transformations 
are therefore applied that move and warp the images 
such that they all conform (approximately) to some 
standard brain. Th   is normalisation facilitates intersubject 
averaging. Th   e normalising transformations can be 
computed on the basis of the PET data themselves on the 
basis of co-registered high-resolution anatomical MRI. 
Convolving the data with a smoothing kernel has several 
important objectives. First, it generally increases the 
signal relative to noise. Second, convolving with a Gaus-
sian kernel conditions the data to conform more closely 
to a Gaussian ﬁ   eld model, even though this reduces 
spatial resolution.
Th   e aim of the analysis is to identify areas of cerebral 
[11C]PIB binding that were signiﬁ  cantly  diﬀ  erent  in 
patients compared with the controls. Signiﬁ  cant diﬀ  er-
ences between patients and control subjects were estima-
ted according to the general linear model at each and 
every voxel [36]. Comparison between patients and 
controls as groups was performed without using analysis 
of covariance. Linear contrasts were used to test the 
hypotheses for speciﬁ  c focal eﬀ  ects. Th   e resulting set of 
voxel values for each contrast constitutes a statistical 
parametric map of the t statistic SPM[t].
Spatially normalised RATIO images could be inter-
rogated using diﬀ  erent thresholds. Here we have used a 
threshold of P <0.00001 with an extent threshold of 200 
Figure 6. Rat  io maps. Ratio images from the [11C]Pittsburgh Compound B ([11C]PIB) scans of the two subjects shown in Figure 3: top images, 
control subject; bottom images, Alzheimer’s disease (AD) patient. Images generated by dividing the mean activity concentration of each voxel 
from 40 to 60 minutes post injection (centre) or from 60 to 90 minutes post injection (right) by the mean activity concentration of cerebellar grey 
matter (white arrow) of the same time interval. The T1-weighted structural magnetic resonance (MR) images in the left column are shown for 
reference only. The colour bars at the bottom of the columns indicate the image minimum and maximum ratios. A visual comparison with the 10 to 
90 minute sum images shown in Figure 3 immediately reveals the much higher levels of image noise in these late images due to the 11C half-life of 
20.4 minutes.
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analysis of covariance or proportional scaling. Figure 7 
shows [11C]PIB uptake was high in AD patients com  pared 
with the healthy control subjects in frontal, temporal, 
parietal and occipital cortices. SPM was not able to 
interrogate the parametric images at a lower threshold 
for signiﬁ  cance.  [11C]PIB also showed a signiﬁ    cant 
increase in mild cognitive impairment subjects, as 60% of 
these patients had signiﬁ  cantly increased levels compared 
with those of AD.
Newer amyloid tracers
A ﬂ  uorinated derivative of PIB, [18F]ﬂ  utemetamol, is now 
being developed and studied [37]. Since the half-life of 
this compound is considerably higher than carbon-11 
com  pounds, a cyclotron is not necessary for routine 
studies as this could be manufactured at one site and 
could be distributed. [18F]Flutemetamol is analysed using 
the target to cerebellar ratio similar to [11C]PIB [38]. 
Other ﬂ  uorinated compounds widely tested for amyloid 
imaging include [18F]AV-45 [39,40] and ﬂ  orbetaben [41]. 
A head-to-head comparison of [18F]AV-45 against 
[11C]PIB is now underway. Several other imaging agents 
are also in development.
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